ClinicalTrials.gg
Drug

Risankizumab clinical trials

Also written ABBV-066, SKYRIZI and BI 655066.

studies test it
77
open now
13
in phase 3
32
first study started
2012

How each study uses risankizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the risankizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
23 Apr 2019 · SKYRIZI · BLA 761105 (FDA, Drugs@FDA)
European Union
26 Apr 2019 · Skyrizi · EMEA/H/C/004759 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Risankizumab
67
risankizumab SC
6
risankizumab IV
5
ABBV-066 BI 655066
3
risankizumab-rzaa
2

Brand

SKYRIZI
47

Development codes

ABBV-066
49
BI 655066
29

Studies by the year they started

77 studies that test it; most in 2016 (8)

Studies that test risankizumab, by start year
YearStudies
20121
20144
20153
20168
20177
20187
20198
20208
20216
20221
20234
20247
20258
20265

By phase

A phase 1/2 study counts in both.

Phase 1
18
Phase 2
18
Phase 3
32
Phase 4
9
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 67 · Other 10

AbbVie (64) · Janssen Research & Development, LLC (2) · Jaehwan Kim (1) · Radboud University Medical Center (1) · Oregon Medical Research Center (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Boehringer Ingelheim (1) · University of California, San Francisco (1)

Often tested with

Tested in the same studies.

Guselkumab (5) · Secukinumab (3) · Ixekizumab (3) · Bimekizumab (3) · Adalimumab (3) · Deucravacitinib (2) · Tildrakizumab (2) · Tacrolimus (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Risankizumab is the comparator. A study of two new drugs counts under both.

  • 1Sonelokimab · MoonLake Immunotherapeutics AG · next primary completion Jan 2027
Reaching primary completion within a year · 3, 2 in phase 3

Studies that test risankizumab, phase 3 first.

Studies

Open first, then newest update. How each study uses risankizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 77

See all 77 studies that test risankizumab →

Given beside what is tested · 2 — risankizumab is usual care or a partner of the new treatment
As the comparator · 3 — what is tested is compared with risankizumab

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call risankizumab · ClinicalTrials.gg INT000320

  • MeSH (NLM) C000601773risankizumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 90ZX3Q3FR7RISANKIZUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 2166040Confirmed FDA, Wikidata
  • Wikidata Q25112466risankizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C152227RisankizumabOne source FDA
  • DrugBank DB14762One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.